Healthcare stocks: ranking by score
MeridIAn analyzes 217 Healthcare companies from 19 countries. Their average score is 5.4 out of 10, below the whole ranking (5.8). The best scored right now are Bristol-Myers Squibb (7.9), Ipsen (7.7) and Exelixis (7.6). Half of them trade below a P/E of 26.7 and the median yield among dividend payers is 1.2%. By country, most come from United States (130) and Switzerland (17).
Top 25 by score
| # | Company | Country | Score | P/E | Div. | Market cap |
|---|---|---|---|---|---|---|
| 1 | Bristol-Myers SquibbBMY | United States | 7.9 | 13.1 | 4.2% | $121.7B |
| 2 | IpsenIPN.PA | France | 7.7 | 23.1 | 1.1% | $13.2B |
| 3 | ExelixisEXEL | United States | 7.6 | 18.6 | – | $14.6B |
| 4 | OrionORNBV.HE | Finland | 7.6 | 19.1 | 2.3% | $12.5B |
| 5 | IncyteINCY | United States | 7.5 | 14.4 | – | $22.9B |
| 6 | Jazz PharmaceuticalsJAZZ | Ireland | 7.5 | 15.2 | – | $14.4B |
| 7 | Halozyme TherapeuticsHALO | United States | 7.4 | 32.1 | – | $12.5B |
| 8 | H. LundbeckHLUN-B.CO | Denmark | 7.4 | 11.7 | 2.5% | $6.8B |
| 9 | AmgenAMGN | United States | 7.3 | 25.3 | 2.5% | $220.3B |
| 10 | Neurocrine BiosciencesNBIX | United States | 7.3 | 20.7 | – | $14.4B |
| 11 | Clínica BavieraCBAV.MC | Spain | 7.1 | 19.0 | 2.9% | $977.0M |
| 12 | Lantheus HoldingsLNTH | United States | 7.1 | 24.2 | – | $6.5B |
| 13 | Laboratorios Farmacéuticos ROVIROVI.MC | Spain | 7.1 | 16.1 | 1.7% | $3.3B |
| 14 | ArgenxARGX.BR | Netherlands | 7.0 | 32.7 | – | $51.6B |
| 15 | GileadGILD | United States | 7.0 | – | 2.2% | $182.4B |
| 16 | RocheROP.SW | Switzerland | 6.9 | 23.3 | 2.7% | $343.4B |
| 17 | ChemedCHE | United States | 6.8 | 25.1 | 0.6% | $6.5B |
| 18 | MedtronicMDT | Ireland | 6.8 | 21.6 | 3.3% | $112.2B |
| 19 | RegeneronREGN | United States | 6.8 | 18.3 | 0.5% | $76.1B |
| 20 | UCBUCB.BR | Belgium | 6.8 | 17.8 | 0.7% | $43.2B |
| 21 | ZoetisZTS | United States | 6.8 | 12.0 | 2.9% | $30.2B |
| 22 | AbbVieABBV | United States | 6.7 | 77.0 | 2.5% | $481.4B |
| 23 | Fielmann GroupFIE.DE | Germany | 6.7 | 14.9 | 3.7% | $3.5B |
| 24 | Johnson & JohnsonJNJ | United States | 6.7 | 29.7 | 2.1% | $618.1B |
| 25 | Novo NordiskNVO | Denmark | 6.7 | 9.3 | 4.7% | $168.6B |
Where it stands out
It scores better than the whole ranking on risk & context (7.1 vs 6.4), and worse on dividend (1.5 vs 4.9) and valuation (4.7 vs 5.3).
| Category | Healthcare | Whole ranking |
|---|---|---|
| Financial health | 6.5 | 6.2 |
| Quality / Moat | 5.5 | 5.9 |
| Valuation | 4.7 | 5.3 |
| Growth | 6.6 | 6.6 |
| Dividend | 1.5 | 4.9 |
| Momentum | 6.2 | 6.0 |
| Risk & Context | 7.1 | 6.4 |
Median of each category (0 to 10)
Highest dividend yields
By country
Other sectors
Other screeners
The score sums up, from 0 to 10, what the analysis says about each company; each company page explains it category by category. What does each figure mean? Metrics glossary →
General information for educational purposes, not investment advice. Figures from the latest weekly analysis (Oct 8, 2026) with the latest available price.